Background: Psychodynamic psychotherapy has been used to treat depression for more than a century. However, not all patients respond equally well, and there are few reliable predictors of treatment outcome. Methods: We used resting 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) scans immediately before and after a structured, open trial of brief psychodynamic psychotherapy (n = 16) in conjunction with therapy process ratings and clinical outcome measures to identify neural correlates of treatment response. Results: Pretreatment glucose metabolism within the right posterior insula correlated with depression severity. Reductions in depression scores correlated with a pre- to posttreatment reduction in right insular metabolism, which in turn correlated with higher objective measures of patient insight obtained from videotaped therapy sessions. Pretreatment metabolism in the right precuneus was significantly higher in patients who completed treatment and correlated with psychological mindedness. Conclusions: Resting brain metabolism predicted both clinical course and relevant psychotherapeutic process during short-term psychodynamic psychotherapy for depression.

Keywords:
Psychotherapy, Depression, Positron emission tomography
1.
Leichsenring F, Rabung S: Effectiveness of long-term psychodynamic psychotherapy: a meta-analysis. JAMA 2008;300:1551-1565.
2.
Driessen E, Cuijpers P, de Maat SC, Abbass AA, de Jonghe F, Dekker JJ: The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis. Clin Psychol Rev 2010;30:25-36.
3.
Roos J, Werbart A: Therapist and relationship factors influencing dropout from individual psychotherapy: a literature review. Psychother Res 2013;23:394-418.
4.
Swift JK, Greenberg RP: Premature discontinuation in adult psychotherapy: a meta-analysis. J Consult Clin Psychol 2012;80:547-559.
5.
Roffman JL, Marci CD, Glick DM, Dougherty DD, Rauch SL: Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol Med 2005;35:1385-1398.
6.
Abbass AA, Nowoweiski SJ, Bernier D, Tarzwell R, Beutel ME: Review of psychodynamic psychotherapy neuroimaging studies. Psychother Psychosom 2014;83:142-147.
7.
Book HE: How to Practice Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method. Washington, American Psychological Association, 1998.
8.
Jones EE, Pulos SM: Comparing the process in psychodynamic and cognitive-behavioral therapies. J Consult Clin Psychol 1993;61:306-316.
9.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
10.
Conte HR, Ratto R, Karasu TB: The psychological mindedness scale: factor structure and relationship to outcome of psychotherapy. J Psychother Pract Res 1996;5:250-259.
11.
Hatcher RL, Gillaspy JA: Development and validation of a revised short version of the working alliance inventory. Psychother Res 2006;16:12-25.
12.
Luborsky L, Barber JP, Crits-Christoph P: Theory-based research for understanding the process of dynamic psychotherapy. J Consult Clin Psychol 1990;58:281-287.
13.
Mayberg HS: Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003;65:193-207.
14.
Craig AD: How do you feel - now? The anterior insula and human awareness. Nat Rev Neurosci 2009;10:59-70.
15.
Lutz A, Brefczynski-Lewis J, Johnstone T, Davidson RJ: Regulation of the neural circuitry of emotion by compassion meditation: effects of meditative expertise. PLoS One 2008;3:e1897.
16.
Avery JA, Drevets WC, Moseman SE, Bodurka J, Barcalow JC, Simmons WK: Major depressive disorder is associated with abnormal interoceptive activity and functional connectivity in the insula. Biol Psychiatry 2014;76:258-266.
17.
McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, Craddock RC, Mayberg HS: Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013;70:821-829.
18.
Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, Mayberg H: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004;61:34-41.
19.
Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR Jr: Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001;58:631-640.
20.
Bullmore E, Sporns O: Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci 2009;10:186-198.
21.
Cavanna AE, Trimble MR: The precuneus: a review of its functional anatomy and behavioural correlates. Brain 2006;129:564-583.
22.
Tillett R: Assessment and outcome in psychotherapy. Curr Opin Psychiatry 1993;6:353-357.
23.
Valbak K: Suitability for psychoanalytic psychotherapy: a review. Acta Psychiatr Scand 2004;109:164-178.
24.
Ablon JS, Jones EE: Validity of controlled clinical trials of psychotherapy: findings from the NIMH treatment of depression collaborative research program. Am J Psychiatry 2002;159:775-783.
25.
Serralta FB, Pole N, Tiellet Nunes ML, Eizirik CL, Olsen C: The process of change in brief psychotherapy: effects of psychodynamic and cognitive-behavioral prototypes. Psychother Res 2010;20:564-575.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.